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Abstract  
Background: To inform the development of the European Academy of Allergy and Clinical 
Immunonology’s (EAACI) Guidelines on Allergen Immunotherapy (AIT) for allergic asthma, we assessed 
the evidence on the effectiveness, cost-effectiveness and safety of AIT.   
Methods: We performed a systematic review, which  involved searching nine databases.  Studies were 
screened against pre-defined eligibility criteria and critically appraised using established instruments.  Data 
were synthesized using random-effects meta-analyses. 
Results: 98 studies satisfied the inclusion criteria. Short-term symptom scores were reduced with a 
standardized mean difference (SMD) of -1.11 (95%CI -1.66, -0.56).  This was robust to a pre-specified 
sensitivity analyses, but there was evidence suggestive of publication bias. Short-term medication scores 
were reduced SMD -1.21 (95%CI -1.87, -0.54), again with evidence of potential publication bias.  There 
was no reduction in short-term combined medication and symptom scores SMD 0.17 (95%CI -0.23, 
0.58), but one study showed a beneficial long-term effect.  
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For secondary outcomes subcutaneous immunotherapy (SCIT) improved quality of life and decreased 
allergen specific airways hyperreactivity (AHR) but this was not the case for sub-lingual immunotherapy 
(SLIT). There were no consistent effects on asthma control, exacerbations, lung function, and non-
specific AHR.  
AIT resulted in a modest increased risk of adverse events (AEs). Although relatively uncommon, systemic 
AEs were more frequent with SCIT; however no fatalities were reported.  
The limited evidence on cost-effectiveness was mainly available for sublingual immunotherapy (SLIT) and 
this suggested that SLIT is likely to be cost-effective. 
Conclusions: AIT can achieve substantial reductions in short-term symptom and medication scores in 
allergic asthma.  It was however associated with a modest increased risk of systemic and local AEs.  More 
data are needed in relation to secondary outcomes, longer-term effectiveness and cost-effectiveness.  
 
Keywords: allergy, allergen immunotherapy, asthma, cost-effectiveness, desensitization, effectiveness, 
exacerbations, lung function, quality of life, safety. 
 
BACKGROUND  
Asthma is a major public health problem affecting over 300 million people worldwide.(1) Its prevalence 
and impact are particularly on the rise and it is estimated that by 2025 an additional 100 million people 
may develop asthma.(2) Asthma  is therefore set to become one of the world’s most prevalent chronic 
diseases. 
Based on the clinical history, examination and investigative procedures, different asthma phenotypes have 
been described.(3)  The pathogenesis of asthma is extremely complex and several disease endotypes have 
been suggested.(3,4) Allergic asthma is one of best described asthma phenotypesof primary studies. 
Allergic sensitization is a strong risk factor for asthma inception and severity in children and in adults.(5) 
Current asthma therapies can effectively control symptoms and the ongoing inflammatory process but do 
not affect the underlying, dysregulated immune response. Thus, they are very limited in controlling the 
progression of the disease. Allergen immunotherapy (AIT) is the only etiology-based treatment for 
allergic diseases capable of disease modification, as demonstrated by prevention of both the onset of new 
allergic sensitizations and disease progression.  
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The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing 
Guidelines on Allergen Immunotherapy (AIT) for Allergic Asthma.  We undertook a systematic review of primary 
studies on the effectiveness, cost-effectiveness and safety of AIT for allergic asthma in order to inform 
the formulation of key clinical recommendations.    
METHODS  
A detailed outline of the methods have previously been published in the protocol of this review.(6) We 
therefore confine ourseleves to a synopsis of the methods employed.   
A highly sensitive search strategy was developed, and validated study design filters were applied to retrieve 
articles pertaining to the use of AIT for  allergic asthma from electronic bibliographic databases.  The 
search strategy was developed on OVID MEDLINE and then adapted for the other databases (see 
Appendix 1, Supplementary file). In all cases, the databases were searched from inception to October 31, 
2015.  Additional papers were located through searching the references cited by the identified studies, and 
unpublished work and research in progress was identified through discussion with experts in the field.   
There were no language restrictions employed.  
Inclusion  and exclusion criteria are detailed in Box 1 
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Patient 
characteristics 
 
Studies conducted on patients of any age with a physician confirmed diagnosis of asthma, 
plus evidence of clinically relevant allergic sensitization as assessed by an objective 
biomarker (e.g., skin prick test or specific-IgE), in combination with a history of asthma 
symptoms due to allergen exposure 
Interventions 
of interest  
 
AIT for different allergens (e.g. pollens, house dust mites (HDM), animal dander, 
cockroach and molds), administered through either subcutaneous (SCIT) or sublingual 
(SLIT) routes. 
Comparator Placebo or any active comparator. 
Study designs  
 
Effectiveness: Double-blind randomized controlled trials (RCTs). Originally, we planned to 
include data from any RCT, irrespective of whether there was blinding.  This was changed 
due to the large volume of RCT studies. This decision was made prior to any analyses being 
undertaken.  
Cost-effectiveness: Health economic analysis.  
Safety: Double-blind RCTs and large case series (≥300 patients). 
Outcomes 
 
Primary outcomes: Effectiveness, both short-term (i.e. during treatment) and long-term (i.e. at 
least a year after discontinuation of AIT)  as assessed by symptom and/or medication 
scores.   
Secondary outcomes: Asthma control; asthma specific quality of life (QoL); exacerbations; lung 
function; response to environmental exposure chamber or bronchial allergen challenge; 
health economic analysis from the perspective of the health system/payer; and safety as 
assessed by local and systemic reactions.(7,8) 
Exclusion 
criteria 
Reviews, discussion papers, non-research letters and editorials, animal studies and studies 
not employing double-blind RCT designs. 
 
Box 1. Inclusion and exclusion criteria 
 
Study selection 
All references were uploaded into the systematic review software DistillerSR and underwent de-
duplication.  Studies were independently checked by two reviewers (SD, FA or AK) against the above 
inclusion criteria. Any discrepancies were resolved through discussion and, when necessary, a third 
reviewer was consulted (AS).   
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Quality assessment 
Quality assessments were independently carried out on each study by two reviewers (FA, AK, DD, SD or 
MK).  We used the Cochrane Risk of Bias (ROB) tool to assess RCTs,(9) the Critical Appraisal Skills 
Programme (CASP) Economic Evaluation Checklist for health economic studies ,(10) and the National 
Institute for Health and Clinical Excellence (NICE) quality assessment tool to critically appraise case 
series.(11) Any discrepancies were resolved by discussion or arbitration by a third reviewer (AS). 
 
Data extraction, analysis and synthesis 
Data were independently extracted onto a customized data extraction sheet in DistillerSR by two 
reviewers (FA, AK, HZ, DD or SD) and any discrepancies were resolved by discussion or arbitration by a 
third reviewer (AS).  A descriptive report with summary data tables was produced to summarize the 
literature.  Where clinically and statistically appropriate, meta-analyses were undertaken using random-
effects modeling.(12) Where standardized mean difference (SMD)has been used the scale used is 0.2 
represents a small effect size, 0.5 a medium effect size and 0.8 a large effect size. (105) 
Sensitivity and assessment for publication bias 
Sensitivity analyses were, where possible, undertaken by comparing the summary estimates obtained by 
excluding studies judged to be at high ROB with those judged to be at low or moderate ROB.   
Where possible, publication bias was assessed through the creation of funnel plots, and tested by Begg's 
rank correlation test and Egger's regression test.(13,14) 
Subgroup analyses 
A number of sub-group analyses were undertaken,details of which are in the protocol. 
Registration and reporting 
This review has been registered with the International Prospective Register of Systematic Reviews 
(PROSPERO): CRD42016035372.  The Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) checklist was used to guide the reporting of the systematic review (Appendix 2, 
Supplementary file). 
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RESULTS 
Our search strategy yielded 7,490 papers of which 98 studies were eligible; these comprised of 89 double-
blind RCTs (reported in 94 papers), three cost-effectiveness studies and six case series (see Figure 1).  
 
Effectiveness 
Description of studies 
The RCTs enrolled a total of 7,413 patients. The route of administration of AIT was SCIT (n=54), SLIT 
(n=34), and SCIT versus SLIT (n=1). The  majority of trials reported on the short-term effectiveness of 
AIT with only one SLIT trial reporting on long-term effectiveness. The 54 SCIT trials (reported in 57 
papers) included 2,305 patients.(15–70)  and the 34 SLIT trials (71–104)(reported in 36 papers) included 
5,108 patients. SCIT studies included adults (n=24), both children and adults (n=17), and children 
(n=13). SLIT studies included children (n=20), both children and adults (n=10), and adults (n=4). 
Allergen extracts administered included HDM, grass, cat, dog, trees, molds, latex and weeds. Various AIT 
protocols were utilized. The severity of asthma tended to be mild-to-moderate. Further details are 
included in  Tables 1a, 1b, 1c and S1a, S1b, S1c (Supplementary file). 
Quality assessment 
The majority of SCIT trials (n=32) were judged as unclear ROB, seven  low ROB and 15 studies as at 
high ROB (Table S1d, Supplementary file). Twenty SLIT studies were assessed to be at high ROB; 13 
studies were at unclear ROB; and one study at low ROB (Table S1e, Supplementary file).  The one SCIT 
vs SLIT study was judged to be at a low ROB (Table S1f, Supplementary file).  
Primary outcomes 
Symptom scores 
Short-term  
Fifty-eight (36 SCIT and 22 SLIT ) trials reported on the effect of symptoms at the end of the AIT 
treatment period. We were able to pool data from 15 SCIT and SLIT trials with placebo as comparator. 
The metaanalysis  showed that AIT improved symptom scores with a  standardized mean difference 
(SMD) of -1.11 (95%CI -1.66, -0.56) (Figure 2), these suggesting  a large effect of AIT.(105) 
Sensitivity analysis 
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By excluding studies at high ROB sensitivity analysis confirmed the effect of AIT on asthma symptom 
scores: SMD -1.44 (95%CI -2.14, -0.74) (Figure S2a, Supplementary file).  
Publication bias 
The funnel plot showed possible publication bias as evidenced by an excess of small studies with large 
effect sizes (Figures S2b, Supplementary file). Publication bias was also suggested by the Egger test 
(P=0.024).  There were insufficient studies to undertake the Begg test 
       
Subgroup analyses 
 Children (<18 years) versus adults (≥18 years): SMD -0.58 (95%CI -1.17, -0.01) in children and 
SMD -1.95 (95%CI -3.28, -0.62)) in adults (Figure 3), supporting AIT effectiveness in both 
children and adults. 
 SCIT versus SLIT: the analyses found that SCIT is effective with SMD -1.64 (95%CI -2.51, -
0.78) and suggested (but did not confirm) that SLIT was effective SMD -0.35 (95%CI -0.75, 
0.05)  (Figure 4); this indirect comparison suggested that SCIT was more effective than SLIT.  
 Treatment duration: SMD -1.15 (95%CI -1.77, -0.53) in those treated for <3 years and SMD -
0.79 (95%CI -1.10, -0.49) in those treated for ≥3 years (Figure S2c, Supplementary file), these 
analyses finding that both treatment durations were effective. 
 Mild/moderate versus moderate/severe disease: this subgroup analyses found that  AIT is 
effective for mild/moderate asthma SMD -1.00 (95%CI -1.81, -0.19)   and suggested (but did 
not confirm)  a possible benefit in those with moderate/severe disease SMD -0.23 (95%CI -0.89, 
0.43) (Figure S2d, Supplementary file) 
 Individual allergens: this subgroup analyses found evidence of benefit for AIT with HDM SMD 
-1.41 (95%CI -2.27, -0.55), grass pollen SMD -1.18 (95%CI -2.17, -0.20) and cat/dog dander 
(SMD -0.77 (95%CI -1.48, -0.06)), suggested (but did not confirm) benefit for tree pollen SMD -
0.24 (95%CI -0.91, 0.42), and found no benefit for mold SMD 0.36 (95%CI -0.39, 1.11).  (Figure 
S2e, Supplementary file) 
 Monosensitized/mono-allergic versus polysensitized: there is evidence of AIT benefit in 
monosensitized/mono-allergic patients SMD -4.23 (95%CI -5.53, -2.94) and a suggested benefit 
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(but not confirmed) for  polysensitized patients SMD -0.31 (95%CI -0.65, 0.04) (Figure S2f, 
Supplementary file), 
Long-term  
No studies reported on the long-term effectiveness of AIT on symptom score.  
 
Medication scores 
Short-term   
Forty-two (28 SCIT and 14 SLIT ) studies reported on medication scores.. Pooling of data with placebo 
as the comparator was possible for 10 studies.  Meta-analysis found evidence that AIT improved 
medication scores (i.e. reduced medication use) with a SMD of -1.21 (95%CI -1.87, -0.54) (Figure 5), this 
corresponding to a large effect. 
 
Sensitivity analysis 
Sensitivity analysis for this outcome was not possible as no studies were found to be at high ROB. 
Publication bias 
The funnel plot showed possible publication bias as evidenced by an excess of small studies with large 
effect sizes (Figures S2g, Supplementary file), but this was not confirmed by the Egger test (P=0.09).  
There were insufficient studies to undertake the Begg test. 
Subgroup analyses 
 Children (<18 years) versus adults (≥18 years): there is evidence for benefit in children SMD -
0.49 (95%CI -0.98, 0.00) and a suggested benefit (but not confirmed) in adults SMD -4.45 
(95%CI -11.23, 2.32) (Figure 6) 
 SCIT versus SLIT: SMD -1.65 (95%CI -2.52, -0.79) for SCIT and SMD -0.29 (95%CI -0.82, 
0.24) for SLIT (Figure 7), these analyses showing benefit of  SCIT and suggesting (but not 
confirming) benefit from SLIT. 
 Mild/moderate versus moderate/severe disease: SMD -1.59 (95%CI -2.48, -0.70) for 
mild/moderate disease and SMD -0.36 (95%CI -1.03, 0.31) (Figure S2h, Supplementary file), 
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these analyses showing a benefit in those with mild/moderate disease and suggesting (but not 
confirming) benefit in those with moderate/severe disease. 
 Treatment duration: SMD -1.21 (95%CI -1.94, -0.49) for those treated for <3 years andSMD -
1.29 (95%CI -2.00, -0.59) for those receiving ≥3 years of treatment (Figure S2i, Supplementary 
file), these analyses showing evidence of benefit in both groups. 
 Individual allergens: this subgroup analysis demonstrated a benefit of AIT with  HDM (SMD -
2.10 (95%CI -3.29, -0.91) and tree pollen (one study) (SMD -1.08 (95%CI -1.79, -0.37)) and 
suggested (but not confirmed) a benefit for, grass pollen (SMD -0.06 (95%CI -0.41, 0.28)) and 
molds (SMD -0.65 (95%CI -1.92, 0.62) (Figure S2j, Supplementary file).  
 Monosensitized and mono-allergic versus polysensitized: SMD -1.18 (95%CI -1.16, 0.13) in 
mono-sensitized and mono-allergic and the polysensitized group (SMD -0.36 (95%CI -2.11, 
0.25)) in the polysensitized group (Figure S2k) these analyses suggesting (but not confirming) 
benefit in both groups.  
 
Long-term  
 
No studies reported on the long-term effectiveness of AIT on medication score. 
 
Combined symptom and medication scores 
Short-term  
Six studies (two SCIT, three SLIT studies and one SCIT vs. SLIT) reported a combined assessment of the 
effectiveness of AIT on symptoms and medication usage. Pooling of data was possible for two studies, 
this showing a SMD of 0.17 (95%CI -0.23, 0.58) (Figure 8). 
Sensitivity analysis, assessment of publication bias and subgroup analyses 
These analyses were not possible for this outcome. 
Long-term  
One SLIT study at low ROB reported on this outcome. A five-year double blind placebo RCT by 
Durham (2012) had a three year SLIT tablets or placebo treatment period in grass pollen allergic patients 
followed by a two-year blinded observation period when no active treatment was administered. At the 
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end of the five years the group who had received SLIT were found to have a significant improvement in 
combined asthma symptom and medication scores when compared to placebo for the whole five-year 
period (p=0.049). 
Secondary outcomes 
Asthma control 
 
Seven SLIT studies reported on a measure of asthma control  (see Table S1g for details). 
(77,78,85,88,93,98,100). We were unable to pool data due to the differences in reporting of results. The 
one study at low ROB found that AIT did not improve asthma control(98) .  We found no evidence to 
assess whether SCIT is effective in improving asthma control in allergic asthma patients. 
Quality of life 
Eleven AIT trials reported on a measure of  disease-specific QoL (Table S1h).   
Three SCIT studies (19,35,106), all judged to be at low ROB, reported significant improvements in 
disease-specific QoL. Pooled data from two of these trials (19,35), showed a large treatment effect with 
an SMD of -0.83 (95%CI -1.19, -0.47) in favor of SCIT (Figure 9).  
Seven SLIT trials  reported on disease-specific QoL (77,78,83,88,93,98,100).  We were unable to pool data 
from these studies for meta-analysis due to the variable reporting of results (Table 2). The one low ROB 
trial of SLIT(98)  showed no significant improvement in disease-specific QoL.  
Exacerbations 
Six trials (69,78,80,88,91,98) reported on asthma exacerbations, which were defined in a number of ways 
(Table S1i).  The one SCIT trial at low ROB (69) reported on exacerbations defined by the number of 
courses of oral corticosteroids required to restore asthma control  found no significant difference 
between the SCIT and placebo groups (P-value not given).  Five SLIT studies reported on exacerbations, 
which we were unable to pool due to variations in the ways in which trial results were reported.  
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In summary, focusing on the trials at low ROB, the Wang (2006) SCIT trial failed to demonstrate 
evidence of a reduction in exacerbations in those treated with AIT compared with those treated with 
placebo.  Two SLIT trials reported a positive effect of AIT on asthma exacerbations, one in the context 
of reducing the dose of ICS.  
Lung function 
Twenty-five studies, of variable quality, reported on measures of lung function: peak expiratory flow rate 
(PEF), forced expiratory volume  in  1 second (FEV1) and forced expiratory flow at 25–75% of forced 
vital capacity (FEF 25-75%). Data on these outcomes were recorded in a number of ways and at varying 
times throughout the study.  
Peak expiratory flow rate (PEF) 
Fourteen studies reported on this outcome.(16,29,38,43,48,50,61,69,72,73,93,96,107,108) (Table S1j).  
Pooled data from six studies suggested no clear benefit of AIT with a SMD of 0.48 (95%CI -0.21, 1.18) 
(Figure S4a) 
Forced expiratory volume (FEV1) 
Nine studies reported on FEV1. Reporting of data was varied (18,28,43,57,73,93,96,108,109) (Table S1k).  
Data pooled from two studies indicated no clear evidence of benefit associated with AIT with a SMD of 
0.41 (95%CI -0.46, 1.27) (Figure S4a)  
Forced expiratory flow at 25–75% of forced vital capacity (FEF25-75) 
We were able to pool data on FEF 25-75 from three trials (72,96,109) and found an SMD of 0.83 (95%CI 
0.31, 1.35), this suggesting a large beneficial effect of AIT (Figure S4a).  
 
In summary, the evidence identified from meta-analysis evaluating the effect of AIT on lung function in 
allergic asthma supports the effectiveness of AIT on small airways (FEF 25-75%), but with no clear 
evidence of benefit on improving PEF or FEV1.  
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Bronchial provocation tests 
Thirty-one trials reported on bronchial provocation tests. Twenty-one trials looked at allergen specific 
provocation tests and 18 studies evaluated non-specific measures of bronchial hyperreactivity. There was 
a wide variation in reporting of outcome data (Tables S1l and S1m). 
Allergen specific airway hyperreactivity 
Twenty-one trials performed allergen specific bronchial provocation tests (15,17–
20,25,30,31,35,44,48,53,60,62,64,67,70,82,107,108,110). They were of variable quality and were mainly 
SCIT  trials (n=20), SLIT being evaluated in only one trial (82). (Table S1l).  
Pooled data from three SCIT studies, demonstrated a large effect of AIT with a  SMD of 0.93 (95%CI 
0.08, 1.79) (Figure S4b). Furthermore, there was evidence from eight high quality RCTs that SCIT was 
effective in reducing allergen specific bronchial reactivity in patients with allergic asthma 
One SLIT study reported on allergen specific bronchial responsiveness to Artemisia pollen (Leng 1990).  
This study, at moderate ROB, found no significant difference between the SLIT and placebo groups.  
Non- specific airway hyperreactivity 
Eighteen studies reported on this outcome (16–18,20,33,36,48,55,62,67,69,72,73,94,96,106,109,110) 
(Table S1m).  
Pooling of data was possible for metacholine PC20 for three studies which showed an SMD of 0.74 
(95%CI -0.17, 1.66) , showing no clear evidence of benefit for AIT; Histamine PC20 for two studies with 
an SMD of 0.33 (95% CI 0.03, 0.64) favouring AIT and for metacholine PD20 for two studies showing 
an SMD of 0.03 (95%CI -0.32, 0.39) showing no clear evidence in favour of AIT (Figure S4c). We were 
able to combine data from seven of these studies which showed an overall SMD of 0.33 (95%CI 0.01, 
0.64) in favour of AIT (Figure S4d) 
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Cost-effectiveness 
One SCIT and two SLIT studies satisfied the eligibility criteria. (111–113) These included children and 
adults with or without allergic rhinitis (Tables S1m and S1n). The quality appraisal is detailed in Tables  
S1o and S1p. 
Of the three studies included only one focused on patients with allergic asthma who did not also have 
allergic rhinitis.(111)  This study was carried out in Germany and compared SCIT with standard care 
based on a small scale RCT (N=65) with three years of follow-up data. The study used a disease specific 
outcome measure (i.e. mean morning peak flow) with no attempt to convert it to a general quality of life 
measure such as quality adjusted life years (QALYs) making it impossible to assess the cost-effectiveness 
of the treatment. The study found that, over the three years, SCIT was more expensive than standard care 
and performed better than standard care on the disease specific outcome measure. 
The remaining two studies looked at patients with both asthma and allergic rhinitis. SLIT was compared 
with  standard care in an RCT (N=151) with one year of follow-up conducted in Austria, Denmark, 
Germany, Holland, Italy, Spain, Sweden and the UK, and with results evaluated from an English National 
Health Service (NHS) perspective.(112)  This study used one year of treatment data and assumed a 
constant treatment effect over the three year treatment period and the six years following the end of the 
treatment. EQ5D was used to evaluate the treatment outcome. The incremental cost-effectiveness ratio 
(ICER) of SLIT, as compared to standard care at 2005 prices, was calculated at £8816 (€10850) per 
QALY over the nine year period. The study did not attempt to characterize the uncertainty around this 
estimate. Updating this to 2014/15 prices using Personal Social Services Resource Unit (PSSRU) NHS 
inflation indices gave an ICER of £10726 (€13202) per QALY.  Another RCT (N=70) with five years of 
follow-up conducted in Italy comparing SLIT with standard care in patients with asthma and rhinitis  and 
found that patients on SLIT cost less and experienced less symptoms than those on standard care.(113)  
Methods for calculationg the costs were not presented in enough detail to understand the analysis that 
had been performed and there was no attempt to convert the symptom score to a general quality of life 
scale making it impossible to assess the cost-effectiveness of SLIT. 
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Safety 
Data from randomized controlled trials (RCTs) and case series were included to assess the safety of AIT.   
 
RCTs 
Fifty-two RCTs (36 SCIT studies and 16 SLIT) reported safety data  (Tables S3a-f). We were able to pool 
data from 38 of these studies (SCIT=29;SLIT=9) including both local and systemic adverse events (AEs) 
Risk of patients experiencing one or more AE 
AIT delivered by any route (SCIT or SLIT) increased the risk of patients experiencing one or more AE 
(i.e. local and systemic) with a  rate ratio (RR) of 1.74 (95%CI 1.38, 2.2) (Figure S3a). Subgroup analysis 
found that the increased risk was higher for  SCIT RR=2.22 (95% CI 1.48, 3.33) than SLIT RR=1.49 
(95%CI 1.13, 1.98), although this is an indirect comparison.(Figures S3b and S3c) 
Total number of  AEs reported 
AIT delivered by any route (SCIT or SLIT) increased the risk of total AEs (i.e. local and/or systemic) 
with a RR=1.50 (95%CI 1.12, 2.02) (Figure S3d). Subgroup analysis found increased risk both for SCIT( 
RR=1.32 (95%CI 1.01, 1.74) and SLIT (RR=1.93 (95%CI 0.95, 3.95) . (Figures S3e and S3f).  
Risk of systemic AEs 
AIT delivered by any route (SCIT or SLIT) increased the risk of systemic AEs with a RR of 1.85 (95%CI 
1.20, 2.84) (Figure S3g). Subgroup analysis found that there was clearly an increased risk of systemic AEs 
with SCIT RR=1.92 (95%CI 1.19, 3.09), but not for SLIT RR=1.39 (95%CI 0.67, 2.92) (Figures S3h and 
S3i) 
Risk of local AEs 
AIT delivered by any route was not found to increase the risk of local AEs: RR=1.18 (95%CI 0.83, 1.67) 
(Figure S3j). The available data suggested that the risk of local AEs was however substantially greater in 
those receiving SLIT when compared to those receiving SCIT (Figure S3j). 
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Case-series 
We identified six eligible case-series studies in our searches; SCIT (n=5)and  SLIT (n=1). The main 
characteristics of these studies and quality appraisal are presented in Tables S3g and S3h. The reported 
incidence of local AEs varied from 0.66 per patient and 0.33 per injection to 1.8% The reported incidence 
of systemic AEs varied from 0.0074% to 0.06%  
No deaths from AIT were reported in any of these studies.  
 
DISCUSSION 
Statement of principal findings 
This review has found a substantial body of evidence showing that administration of AIT in patients with 
allergic asthma can result in reductions in short-term symptom and medication scores.  These findings do 
however need to be interpreted with caution given that the majority of trials were found to be at high or 
unclear ROB and the possibility of publication bias in relation to both these outcomes.  Further sub-
group analysis confirmed the beneficial effect for SCIT but was questionable for SLIT. There was a more 
modest body of evidence for the combined symptom and medication scores, which meta-analysis 
suggested was ineffective but this was not conclusively demonstrated on account of the wide confidence 
intervals.  We found only one trial, judged to be at low ROB, evaluating long-term outcomes, which 
found a significant improvement in combined symptom and medication scores.  
 
There is evidence for SCIT in  improving  asthma specific quality-of-life and reducing allergen specific 
airway hyperreactivity. In terms of lung function we were unable to demonstrate any significant beneficial 
effect on PEFR and FEV1 however SCIT does have a beneficial effect on FEV25-75. No beneficial 
effect of AIT could be demonstrated on asthma control. As for asthma exacerbations, no beneficial effect 
could be demonstrated for SCIT, but there was limited evidence in favour of SLIT. 
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AIT was associated with a moderate increased risk of AEs, both for SCIT and SLIT. Severe systemic AEs 
were observed, but these were uncommon and mainly occurred with SCIT. No fatalities were reported in 
the studies included in this review.  
 
Strengths and limitations 
To our knowledge, this is the most comprehensive assessment of AIT in asthma ever undertaken.  We 
employed internationally accepted techniques to systematically identify, assess and synthesize a substantial 
body of evidence, which included a number of pre-specified sensitivity and subgroup analyses.   
 
The limitations of this review need to be considered.  First, despite our extensive searches we may not 
have uncovered all relevant evidence on this subject.  Second, we were limited by the heterogeneity in 
approaches used to assess outcomes, which meant we were unable to pool data from all trials or 
undertake all the planned subgroup analyses.  The results of this review, particularly for primary 
outcomes, are based on the trials which we were able to meta-analyse which may not be representative of 
all trials. For example, data for combined scores was only available for six studies of which only two 
could be pooled for meta-analysis the results of which had a wide confidence interval allowing no clear 
conclusion to be drawn. For the subgroup analyses that were undertaken, there was in some cases 
imprecision which impacted on our ability to draw clear conclusions. Third, because of the heterogeneity 
in scoring systems used, we undertook meta-analyses using random-effects modeling and pooled data 
using SMDs, which can be difficult to interpret.  The absolute size of the SMD was used to guide 
assessment of the likely effect size demonstrated. Finally, it needs to be borne in mind that there may 
have been important differences between specific AIT products.  Investigating this issue was how ever 
beyond the scope of this review. 
Interpretaion in the light of the previous literature 
The findings from this review are in keeping with earlier evidence syntheses on this subject (see 
companion paper), which found that SCIT inproved short-term symptom amd medication scores and 
measures of bronchial reactivity, but the evidence for SLIT was less consistent. There was no clear 
improvement of lung function for either SCIT or SLIT.  This present study has built on this body of 
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work by adding a broader range of subgroup analyses, including additional studies at low ROB, and 
achieveing greater precision in summary results.   
Implications for policy, practice and research 
Our findings provide evidence that AIT may be effective in improving  two of our three patient-reported 
primary outcomes over the short-term.  Interpretation of these results is however complicated by 
considerations about the quality of the substantial number of studies and possible publication bias. The 
subgroup analyses suggest that SCIT is likely to be more effective than SLIT, and that AIT may be more 
effective in children than in adults 
Greater standardization of trial designs, looking at the compliance of patients to AIT for the differing 
routes of administration, reporting and choice of outcomes and their reporting so as to facilitate evidence 
syntheses and key subgroup analyses would greatly help to advance the body of evidence underpinning 
AIT in allergic asthma. Future well conducted studies looking at the combined symptom and medication 
score are needed  to determine whether AIT is beneficial for this outcome. We hope that future 
researchers will build on the findings from this systematic review and aim to fill key evidence gaps and 
areas of continuing uncertainty. 
The findings from this review will be used to inform the development of recommendations for EAACI’s 
Guidelines on AIT.  We anticipate that this review will report mid 2017. 
 
Conclusions 
There is evidence that AIT in allergic asthma can achieve substantial reductions in short-term symptom 
and medication scores, with subgroup analyses confirming a benefit from SCIT and a questionable 
benefit from SLIT.  These findings however need to be interpreted with caution given concerns about 
study quality and potential publication bias. Further there is evidence showing that SCIT decreases 
allergen-specific airway hypereactivity and improves asthma specific quality-of-life. The effect of AIT on 
asthma control and exacerbations is not conclusive, neither its long-term efficacy after stopping AIT, 
which requires further investigation. More research is needed to establish the  cost-effectiveness of AIT 
but evidence suggest that SLIT is cost-effective in a UK NHS environment.  
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AIT is associated with a modest increase in the risk of AEs, both for SCIT and SLIT.  Severe systemic 
AEs can occur, but are uncommon and mainly associated with SCIT. No fatalities were reported in the 
studies included in this review.  
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Lyophilised, partially 
purified and biologically 
standardised preparation of 
Cladosporium herbarum 
(Pharmalgen, Pharmacia, 
Uppsala, Sweden) was used.   
        
    
Marques, 
1978, Italy 
 
    X    X  X      X     14 m 
Six syringes numbered in 
order of dose, each 
containing 0.5 ml of D 
pteronyssinus extract 
absorbed into tyrosine 
X      X  
    
Mosbech, 
1989, 
Denmark 
 
    X    X    X    X     2 y 
Biologically standardized 
and purified unmodified Dp 
extract (Pharmalgen). The 
mPEG-modified Dp extract 
was produced by coupling 
activated mPEG-succinate 
to the un- modified Dp 
extract. A buffered solution 
of isotonic saline containing 
0.3 mg/ml albumin, 0.4% 
phenol, and phosphate 0.95 
mg/ml was used for 
mPEG-modified extract. 
X X       
    
Mosbech, 
1990, 
Denmark 
 
    X    X    X         2 y 
Single batch of unmodified, 
purified Dp-extract 
(Pharmalgen)  biologically 
standardized was used. By 
RAST-inhibition, 10-11,000 
BU of this extract equated 
100,000 SQ-U of a similar 
mite allergen extract 
(Aquagen, ALK, Horsholm, 
Denmark). Part of this 
      X  
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batch was modified with 
mPEG (3,000 Daltons).  
The unmodified extract was 
reconstituted in a diluent 
containing 
aluminiumhydroxide, 
whereas no such additive 
was present in the buffered 
saline used for the mPEG-
modified extract. 
Newton, 
1979, UK 
 
    X    X  X           15 m 
Alum-precipitated D. 
farinae 
        
 
 
X 
   
Ohman, 
1984, US 
 
     X   X  X      X     3 m 
Active-treatment vials 
reconstituted in 50% 
glycerine to a concentration 
of 13 units of cat allergen 1 
per millilitre 
      X  
 
 
X 
  
 
X 
 
 
X 
Olsen, 
1997, 
Denmark 
 
    X    X  X      X     1 y 
Active treatment with 
extracts of either 
Dermatophagoides 
pterotryssinus (Dpt) or D. 
farinae (Dfa) (Alutard® SQ, 
ALK, Denmark). 
X X     X  
 
 
 
X 
   
 
X 
Ortolani, 
1984, Italy 
 
X        X  X      X     6 m 
Aqueous lyophilized extract 
(Hollister-Stier, Spokane, 
Washington) of  89 velvet, 
1/3 sweet vernal, and  89 
timothy grass pollen 
X        
    
Pauli, 
1984, (not 
stated. 
Authors from 
France & 
UK)  
 
    X    X  X      X     1 y 
Dpt tyrosine- adsorbed 
extract 
X X       
    
Pene, 1998 
France 
     X   X  X           
6 
week
s 
         Fel d 1 peptides          
    
 
X 
Price, 1984,        
UK 
 
    X    X  X      X     2 y 
Tyrosine glutaraldehyde 
modified D. pteronyssinus 
antigen, "Migen', Bencard. 
 X       
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Rak, 2001, 
Sweden 
 
 X       X  X  X    X      
Standardized depot 
preparations of birch pollen 
allergen extract (Alutard 
SQ, ALKAbelló) containing 
water-soluble allergen 
extract and aluminium 
hydroxide 
X X       
   
 
 
X 
 
 
 
X 
Reid, 1986,         
US 
 
X        X    X    X     8 m 
Seven grass mix in serum, 
plus other allergens specific 
to individuals 
X X     X  
    
Roberts, 
2006, UK 
 
X        X  X       X    2 y 
Alutard SQ P pratense 
(ALK-Abello) was used. 
This is an alum-adsorbed 
preparation of pollen from 
P pratense with a 
recommended dose of 
100,000 SQ-U. 
X X     X  
 
 
X 
 
 
X 
  
Sabbah, 
1991, France 
 
    X    X  X      X     180 d 
Alpha-Fraction-Retard-D. 
pteronyssinus 
X X     X  
    
Smith, 
1971,        
UK 
 
    X    X    X    X      HDM extract X X     X  
    
Sundlin, 
1986, Sweden 
 
     X X   X X      X     18 m 
Partially purified, 
standardized allergenic 
extracts of cat  or dog 
dander 
      X  
   
 
X 
 
 
X 
Tabar, 
2008,  Spain 
 
   X     X  X      X     1 y 
Metabolic extract of A. 
alternata that had been 
biologically standardised 
X X     X  
 
 
X 
   
Taylor, 
1978, US 
 
     X   X  X      X     4 m 1.6 mg/ml cat allergen       X  
 
 
X 
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Taylor, 
1978, UK 
    X    X  X      X     10 w 
HDM fortified house dust 
vaccine 
      X  
 
 
X 
   
Valovirta, 
1984,  
Finland 
 
      X  X  X      X     1 y 
Commercial standardised 
aluminium hydroxide 
bound dog dander extract 
(Alutard SQ) 
        
   
 
X 
 
 
X 
Valovirta, 
1986, Finland 
2nd paper 
original study 
1984 
 
      X  X  X      X     1 y 
Commercial standardised 
aluminium hydroxide 
bound dog dander extract 
(Alutard SQ) 
X      X  
    
Van Bever, 
1992, 
Belgium 
 
    X    X  X        X   1 y 
Aqueous extract of 
Dermatophagoides 
pteronyssinus (10 BU·ml 1) 
X        
 
 
X 
   
 
X 
Van Metre, 
1988, US 
 
     X   X  X      X     2 y 
Cat allergenic extract ALK 
1209/229452 was supplied 
by  Allergologisk 
Laboratories, Copenhagen, 
Denmark 
      X  
 
 
X 
  
 
X 
 
 
X 
Vidal, 2011,   
Spain 
 
    X    X  X           4 m 
D. pteronyssinus extract 
with the major allergens 
Der p 1 and 2 
 X     X  
  
 
X 
  
Wang 2006 
China 
    X    X  X           52w 
Dermatophagoides 
pteronyssinus extract 
X X     X  
 
 
X 
 
 
X 
  
 
X 
Warner, 1978 
UK 
    X    X  X           
1 
year 
D. pteronyssinus absorbed 
into tyrosine (’Migen’, 
Bencard). 
X X     X  
  
 
X 
  
 
X 
 
AIT, allergen specific  immunotherapy; d, day; HDM , house dust mite; m, month; NR, not reported;  SCIT, subcutaneous immunotherapy; SLIT, sublingual immunotherapy; w, week; y, year 
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Table 1b: Overview of SLIT trials (n=34 studies in 36 papers) 
 
Study 
Author, year, 
country 
Allergen(s) type 
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B
ro
n
ch
ia
l  
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st
st
es
ts
 
Alvarez-Cuesta, 
2007, Spain      
X 
  
X 
 
X 
     
X 
    
1 y 
Aqueous solution of 
standardized semi-
purified cat dander 
extract 
X X X 
     
    
Bachelier, 2001, 
Turkey     
X 
   
X 
 
X 
     
X 
    
26 w 
Dermatophagoide(D.pte
ronyssinus)+Dermatoph
agoidesfarinea 
(D. farinea) 50/50 
extract 
X X 
    
X 
 
 
 
 
 
X 
 
 
 
 
X 
  
 
 
X 
Bousquet, 
1999, France     
X 
   
X 
 
X 
     
X 
    
108 w. HDM SLIT X X X 
   
X X 
 
X 
 
X 
  
X 
 
Caffarelli, 2000, 
Italy 
X 
       
X 
 
X 
     
X 
    
13 w 
and 9 
week 
follow 
up 
post 
treatm
ent 
Grass pollen tablet (33% 
Holcus lanatus, 33% 
Phleum pratense and 
33% Poa pratensis) 
X X X 
   
X 
 
    
Cao, 2007, 
China     
X 
   
X 
 
X 
     
X 
    
3 m 
Dermatophagoides 
Farinae Drops  
X 
    
X 
 
 
 
X 
 
X 
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Dahl, 2006, 
Denmark & 
Sweden 
X 
       
X 
 
X 
  
X X 
 
X 
    
19.5 w 
Timothy grass 
(Phleumpratense) 
GRAZAX tablet 75,000 
SQ-T once daily 
X X 
      
    
de Blay, 2014, 
Denmark, 
Germany, Italy, 
Spain, UK, 
Sweden, France 
& Poland 
    
X 
   
X 
 
X 
 
X 
   
X 
    
1 y 
Oral lyophilisates 
containing standardized 
extracts of D 
pteronyssinus and D 
farinae in a 1:1 ratio. 
One development unit 
corresponds to 1 SQ-
HDM 
  
X 
   
X X 
 
 
 
 
X 
 
 
 
 
X 
  
Devillier, 2015, 
China     
X 
   
X 
 
X 
     
X 
    
"52 w 
(+ 12 
week 
baselin
e 
period  
before 
rando
misati
on)" 
HDM SLIT (D. 
pteronyssinus and D. 
farinae), approximately 
28 mcg Der P 1 and 
50mcg Der f 1 daily  
(300 IR) 
      
X X 
 
 
 
 
 
X 
  
 
 
 
 
X 
 
Drachenberg, 
2001, Germany 
X 
       
X 
 
X 
     
X 
    
6 m 
Standardized allergen 
extract (ORALVAC 
birch n = 21 resp. 
grass/rye = 28) 
  
X 
    
X 
    
Durham, 2012 X        X  X   X X  X     
5y(3 
Rx, 2 
follow
up) 
Timothy grass 
(Phleumpratense) 
GRAZAX tablet 75,000 
SQ-T once daily 
     x   
    
Gomez Vera et 
al, 2005, 
Mexico 
    
X 
   
X 
 
X 
     
X 
    
6 m 
Dermatophagoides  
pteronyssinus 1 
standardized  
allergens (IPI-ASAC, 
Mexico) at  
a total dose of 10,469 
UBE 
 
 
X 
    
X 
 
 
 
 
 
X 
  
 
 
 
X 
 
Ippoliti, 2003, 
Italy      
X 
  
X 
 
X 
     
X 
    
26 w 
(with 
3-
month 
run-in) 
HDM SLIT (D. 
pteronyssinus), 
maintenance dose 5 
drops of 10 BU/mL 3 
times a week 
X 
       
 
 
 
X 
   
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved.  
Leng, 1990, 
unclear country   
X 
    
X X 
 
X 
     
x 
    
7.14 w 
(13 w 
post-
treatm
ent 
follow
-up) 
Artemisia pollen SLIT 
daily up-dosing to a 
maximum of 16416 
PNU. Cumulative dose 
396,652.06 PNU 
      
X 
 
    
 
 
 
X 
Lewith, 2002, 
UK     
X 
   
X 
 
X 
         
X 16 w. 
Homeopathic HDM 
SLIT administered on 3 
occasions over 24 hours. 
Dose 30 dilutions of 
1:100 
       
X 
 
 
X 
   
Lue, 2006, 
Taiwan     
X 
   
X 
 
X 
     
X 
    
24 w 
(2 eeks 
post-
treatm
ent 
follow
-up) 
HDM SLIT daily with 3 
week initiation phase. 
Maximum  20 drop dose 
of 300 IR/mL. 
Cumulative dose of 
41,824 IR 
X X 
      
 
 
X 
   
Ma, 2010, 
China     
X 
   
X 
  
X X 
   
X 
    
1 y 
SLIT immunotherapy 
with Der F drops 
X 
     
X 
 
X X   
Ma, 2014, 
China     
X 
   
X 
 
X 
     
X 
    
1 y 
SLIT immunotherapy 
with Der F drops  
X 
    
X 
 
    
Moreno-
Ancillo, 2007, 
Spain 
X 
      
X 
 
X X 
     
X 
    
248 d 
biologically standardized 
by major allergens and 
quantified in 
micrograms, without up-
dosing 
X X X 
     
    
Mosbech, 2014, 
Denmark, 
Germany, Italy, 
Spain, UK, 
Sweden, France 
& Poland 
    
X 
   
X 
 
X 
 
X 
   
X 
    
52 w 
(1 y 
treatm
ent 
durati
on) 
Orallyophilisates 
containing standardized 
extracts of 
Dpteronyssinus and D 
farinae in a 1:1 ratio. 
Three active strengths 
were investigated: 1, 3, 
and 6 SQ-HDM. The 
units were designated in 
development units. One 
development unit 
corresponds to 1 SQ-
HDM. 
X 
     
X X 
 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
 
Mosges et al, 
2010, 
Germany 
X 
       
X 
 
X 
         
X 9 m 
Standardized birch 
pollen (Betula alba) 
allergen extract.  Ultra-
rush high-dose SLIT 
titration regimen 
      
X 
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reaching the 
maintenance dose of 300 
IR 
within 90 min (30–90–
150–300 IR) 
X 
Niu, 2006, 
Taiwan     
X 
   
X 
 
X 
 
X 
        
24 w 
(+2 
week 
off-
treatm
ent 
follow 
up) 
HDM SLIT (D. 
Pteronyssinus  and D. 
farinae), incremental 
dosing up to 
maintenance dose 
(cumulative dose ~ 
41824 IR, which was 
equivalent to 1.7 mg 
D.p. and 3.0 mg D.f.) 
X X 
    
X 
 
 
 
 
 
X 
   
Pajno, 2000, 
Italy     
X 
   
X 
 
X 
 
X 
        
104 w  
HDM SLIT (D. 
pteronyssinus), 
incremental dosing 
schedule followed by 
maintenance 2.4 mg Der 
P 1 and 1.2 mg Der P 2 
per week (in 3 
doses/wk) 
 
X X 
   
X 
 
   
 
 
 
 
X 
 
Pajno, 2002, 
Italy         
X 
 
X 
 
X 
        
56 w 
(with 
52 
week 
off-
treatm
ent 
follow
-up) 
Parietaria pollen SLIT 
(Parietariajudaica), 
incremental dosing 
schedule followed by 
maintenance twice/wk 
(cumulative Par j ~ 20.3 
mcg) 
X X 
      
    
Pajno, 2004, 
Italy 
 
  
X 
    
X X 
 
X 
     
X 
    
56 w  
(with 
52 
week  
off-
treatm
ent  
follow
-up) 
 
Parietaria pollen SLIT 
(Parietaria judaica), 
incremental dosing 
schedule followed by 
maintenance twice/wk 
(cumulative Par j ~ 20.3 
mcg) 
 
        
 
 
 
 
X 
 
 
  
 
 
 
X 
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Pham-Thi, 
2007, France     
X 
   
X 
 
X 
     
X 
    
78 w. 
HDM SLIT (D. 
Pteronyssinus and 
D.farinae), up-dosing for 
2 w up to 300 IR 
concentration once daily 
(average cumulative dose 
was 155,000 IR, 
corresponding to 6.9 mg 
Der P 1 and 14.7 mg 
Der f 1) 
X X 
    
X X 
 
 
 
 
 
X 
 
 
 
 
 
X 
  
Reilly, 1994, 
UK    
X X 
  
X X 
 
X 
     
X 
    
4 w 
(with 4 
w 
'option
al' 
post-
treatm
ent 
follow
-up) 
Homeopathic SLIT 
(allergen varied, decided 
on case-by-case basis; 
HDM (84.6% of 
participants); feathers 
(7.7%); mixed moulds 
(7.7%)). 3 doses in 24 
hours then optionally 
repeated at 4 w 
(according to patient 
choice) 
  
X 
   
  
 
 
 
 
 
X 
   
X 
Reinert, 1983, 
Germany 
X 
       
X 
 
X 
     
X 
    
2 y Troponholistersteir 
  
X 
     
    
Stelmach, 2009, 
Poland 
X 
       
X 
 
X 
         
X 104 w. 
Grass pollen SLIT 
(Dactylisglomerata, 
Anthoxanthumodoratu
m, Loliumperenne, 
Poapratensis, Phleum 
pretense). Ultra-rush 
period(total of 24 0IR). 
At the beginning of the 
next day, every morning 
before breakfast, 
received 4 puffs (120 IR) 
for 6 m. Cumulative 
dose 43,800 IR 
X X 
    
X 
 
 
 
 
 
 
 
X 
   
 
 
 
 
 
X 
Tian, 2014, 
China     
X 
   
X 
 
X 
     
X 
    
48 w. 
HDM SLIT (D. farinae), 
titrated up over the first 
4 w to 333 mcg/mL 
once daily 
X 
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Virchow, 2016, 
Germany     
X 
   
X 
 
X 
          
20 m 
(11 
Augus
t 2011 
to 24 
April 
2013) 
HDM SLIT tablet 
contains extract from 2 
species of cultivated 
HDM (D pteronyssinus 
and D farinae), 
produced in a 
standardized process 
with a 1:1:1:1 ratio of 
the major allergens 
(Group1 allergens of D 
farinae and D 
pteronyssinus and 
Group2 allergens of D 
farinae and D 
pteronyssinus), and 
formulated as rapidly 
dissolving oral 
lyophilisate for 
sublingual 
administration (ALK). 
X 
     
X 
 
   
 
 
 
 
 
 
 
 
 
 
X 
 
Vourdas, 1998, 
Greece  
X 
      
X 
 
X 
          
104 w 
(2 y) 
Olive pollen SLIT, daily 
up-dosing then each 
morning pre- and co-
seasonally from January 
to July for 2 y up to a 
maximum of 20 drops 
of 300 IR (total 30,000 
IR/y) 
X X 
    
X 
 
 
 
 
X 
   
Wang, 2014, 
China  
X 
      
X 
 
X 
          
52 w 
(+12 
w 
baselin
e 
period 
before 
rando
misati
on) 
HDM SLIT 
(D.pteronyssinus and D. 
farinae), approximately 
28 mcg Der P 1 and 50 
mcg Der f 1 daily (300 
IR) 
X X 
    
X X 
 
 
 
 
 
X 
 
 
 
 
 
X 
  
Wood, 201, US 
& UK        
X X 
 
X 
  
X 
 
X 
     
13  w. 
Greer German 
cockroach extract 
 
     
X 
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Zhang, 2013, 
China     
X 
   
X 
  
X 
         
36 m 
Standard 
dermatophagoides  
farinae drops (1~4) 
usage:1~3  
were for increasing 
period of  
treatment for 3 w, 1 
times  
a day.  
 
        
    
Zhang, 2015, 
China     
X 
   
X 
  
X 
         
36 m 
Dermatophagoides 
farina drop  
(1drop/time and 1 
time/day) 
 
        
    
Zheng et al, 
2012, China 
    X    X   X          
36 
month
s 
Standard 
dermatophagoides 
farinae drops 
        
    
 
AIT, allergen specific  immunotherapy; d, day; HDM , house dust mite; m, month; NR, not reported;  SCIT, subcutaneous immunotherapy; SLIT, sublingual immunotherapy; w, week; y, year 
 
 
 
Table 1c: Overview of SCIT vs SLIT trials (n=1) 
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Yukselen,20
12, Turkey 
 
    X    X  X  X    X      
HDM (D. pteronyssinus 
and  D. farinae)  (50/50) for 
sublingual and 
subcutaneous 
administration.  
 
X X     X  
 
 
X 
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Figure 1: PRISMA diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through 
database searching 
N = 7430 
Sc
re
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g 
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cl
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ty
 
Id
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o
n Additional records identified 
through other sources 
N = 60 
Records after duplicates removed 
N = 5997 
Records screened 
N = 5997 
Records excluded 
N = 5683 
Full-text articles 
assessed for eligibility 
N = 314 
Full-text articles 
excluded, with reasons 
N = 216 
Studies included in 
qualitative synthesis 
N = 98  
(54 SCIT, 34 SLIT, 1 SCIT 
vs SLIT, 6 case series, 3 
HE) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
N = 15 
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Figure 2: Meta-analysis of double-blind RCTs for symptom scores comparing AIT (SLIT and 
SCIT) and placebo groups (random effects model) 
 
 
 
 
 
Test of ES=0: z=   3.96 p = 0.000 
Heterogeneity chi-squared = 234.28 (d.f. = 14) p = 0.000 
I-squared (variation in ES attributable to heterogeneity) = 94.0% 
Estimate of between-study variance Tau-squared = 1.0488 
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Figure 3: Meta-analysis of double-blind RCTs, comparing symptom scores between AIT (SLIT 
and SCIT) and placebo groups in children <18 versus adults ≥18  years(random effects model) 
 
 
 
 
Test(s) of heterogeneity: 
  Heterogeneity degrees of 
  Statistic  freedom P Isquared** Tau-squared 
 
Adult  61.83  4  0.000 93.5%  2.0670 
Children                   34.02  4  0.000 88.2%  0.3750 
Overall  104.04  9  0.000 91.3%  0.7215 
 
 
Significance test(s) of ES=0 
 
Adult                 z=  2.87     p = 0.004 
Children              z=  1.93     p = 0.054 
Overall               z=  3.87     p = 0.000 
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Figure 4: Meta-analysis of double-blind RCTs, comparing symptom scores between SCIT versus 
SLIT (random effects model) 
 
  
 
 
 
              Heterogeneity   degrees of 
 Statistic  freedom                     P  Isquared**            Tau-squared 
 
SCIT 137.11  8  0.000  94.2%  1.5937 
SLIT 23.26  5  0.000  78.5%  0.1810 
Overall 234.28  14  0.000  94.0%  1.0488 
 
 
SCIT                  z=  3.71     p = 0.000 
SLIT                  z=  1.71     p = 0.087 
Overall               z=  3.96     p = 0.000 
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Figure 5: Meta-analysis of double-blind RCTs, comparing medication scores between AIT (SLIT 
and SCIT) and placebo groups (random effects model) 
 
 
 
 
 
 
Test of ES=0 : z=   3.56 p = 0.000 
 Heterogeneity chi-squared = 112.48 (d.f. = 9) p = 0.000 
 I-squared (variation in ES attributable to heterogeneity) =  92.0% 
 Estimate of between-study variance Tau-squared =  0.9967 
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Figure 6: Meta-analysis of double-blind RCTs, comparing medication scores between AIT (SLIT 
and SCIT) and placebo groups in children <18 versus adults ≥18  years(random effects model) 
 
 
 
 
                 Het.stat.      df P I-squared** Tau-squared 
 
Adult 35.08 1 0.000 97.1%  23.2029 
Children 15.79 4 0.003 74.7%  0.2244 
Overall 66.41 6 0.000 91.0%  0.9722 
 
 
Adult                 z=  1.29     p = 0.197 
Children              z=  1.96     p = 0.050 
Overall               z=  2.89     p = 0.004 
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Figure 7: Meta-analysis of double-blind RCTs, comparing medication scores between SLIT and 
SCIT  (random effects model) 
 
 
 
 
 
                    Het.  statistic   df     P         I-squared**   Tau-squared 
 
SCIT                66.59          6      0.000      91.0%        1.1642 
SLIT                 7.14           2      0.028      72.0%        0.1553 
Overall            112.48         9      0.000      92.0%        0.9967 
Significance test(s) of ES=0 
 
SCIT                  z=  3.74     p = 0.000 
SLIT                  z=  1.06     p = 0.287 
Overall               z=  3.56     p = 0.000 
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Figure 8: Meta-analysis of double-blind RCTs, comparing combined symptom medication 
scores between AIT (SLIT and SCIT) and placebo groups (random effects model) 
 
 
 
 
 
Test of SMD=0 : z=   0.84 p = 0.400 
 Heterogeneity chi-squared =   0.12 (d.f. = 1) p = 0.728 
 I-squared (variation in SMD attributable to heterogeneity) =   0.0% 
 Estimate of between-study variance Tau-squared =  0.0000 
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Figure 9: Meta-analysis of double blind RCTs of AIT (SCIT and SLIT) versus placebo 
for asthma specific quality of life (random effects model) 
 
 
 
 Test of SMD=0 : z=   4.48 p = 0.000      
  Heterogeneity chi-squared =   0.02 (d.f. = 1) p = 0.893 
  I-squared (variation in SMD attributable to heterogeneity) =   0.0% 
  Estimate of between-study variance Tau-squared =  0.0000 
 
 
 
 
 
